PDCD1 and neoplasm: There were no statistically significant differences in baseline characteristics between the subgroups with different anti-tumor therapy (anti-PD-1 vs anti-PD-1 plus angiogenesis inhibitors), in terms of age, sex, duration of anti-neoplastic therapy sessions and follow-up, baseline HBV DNA level, HBV serum infection markers, the use of antiviral drugs, and history of previous chemotherapy or surgical resection, as well as incidence status (first incidence or recurrence).